Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to -$6.3 million.

  • PAVmed's Net Income towards Common Stockholders changed N/A to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year change of. This contributed to the annual value of $32.4 million for FY2024, which is 14888.18% up from last year.
  • According to the latest figures from Q3 2025, PAVmed's Net Income towards Common Stockholders is -$6.3 million.
  • Over the past 5 years, PAVmed's Net Income towards Common Stockholders peaked at $17.7 million during Q1 2025, and registered a low of -$26.2 million during Q3 2022.
  • For the 4-year period, PAVmed's Net Income towards Common Stockholders averaged around -$13.8 million, with its median value being -$16.4 million (2022).
  • As far as peak fluctuations go, PAVmed's Net Income towards Common Stockholders crashed by 2656.48% in 2024, and later soared by 17767.25% in 2025.
  • PAVmed's Net Income towards Common Stockholders (Quarter) stood at -$20.5 million in 2022, then grew by 22.54% to -$15.9 million in 2023, then skyrocketed by 89.92% to -$1.6 million in 2024, then plummeted by 294.51% to -$6.3 million in 2025.
  • Its last three reported values are -$6.3 million in Q3 2025, -$13.3 million for Q2 2025, and $17.7 million during Q1 2025.